Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04248283 · ClinicalTrials.gov registry record · NA

Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

A NA study of Urinary Incontinence and Urinary Incontinence,Stress, sponsored by Uromedica.

Recruiting
Registry status
NA
Development phase
167
Enrollment target
2
Study locations

NCT04248283 is a NA study of Urinary Incontinence and Urinary Incontinence,Stress that is actively recruiting participants, run by Uromedica. The registered enrollment target is 167 participants, below the 259-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (36% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04248283, a NA study of Urinary Incontinence and Urinary Incontinence,Stress, is actively recruiting participants, sponsored by Uromedica.

RECRUITING
Registry status
NA
Development phase
167 participants
Enrollment target
2
Study locations

Study Summary

A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.

Interventions

  • DEVICE Adjustable Continence Therapy for Women (ACT)

Study Locations (2)

Colorado

  • University of Colorado - Denver

Nebraska

  • CHI Health Research Center - Omaha

Trial Details

FieldValue
Enrollment Target 167 participants
Start Date 2021-01-26
Est. Completion 2025-12-30
Phase NA

Sponsor

Uromedica

4 total trials

What the Registry Record Tells You About NCT04248283

The ClinicalTrials.gov registry entry for NCT04248283 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 259-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (36% lower). The listed sponsor is Uromedica, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Adjustable Continence Therapy for Women (ACT) is the first listed.

NCT04248283 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Colorado, Nebraska.

Frequently Asked Questions

What is clinical trial NCT04248283 about?

NCT04248283 is a clinical study titled "Adjustable Continence Therapy (ACT) for the Treatment of Female SUI". A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.

What is the current status of trial NCT04248283?

This trial is currently recruiting. It is a NA study. The enrollment target is 167 participants. The study started on 2021-01-26. Estimated completion is 2025-12-30.

What conditions does trial NCT04248283 study?

This clinical trial studies the following conditions: Urinary Incontinence, Urinary Incontinence,Stress.

What interventions are being tested in trial NCT04248283?

The interventions under investigation include: Adjustable Continence Therapy for Women (ACT) (DEVICE).

Who is sponsoring clinical trial NCT04248283?

This trial is sponsored by Uromedica, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04248283 being conducted?

This trial has 2 study locations across Colorado, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Incontinence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.